New Study Finds No Tie Between Aluminum-Adjuvanted Vaccines and Autoimmune, Allergic, and Neurodevelopmental Conditions

A new study that took place over 24 years found that there is “no tie between exposure to aluminum-adjuvanted childhood vaccines and autoimmune, atopic or allergic, or neurodevelopmental conditions such as autism.” CIDRAP has the news.

The study comes less than a month after HHS secretary Robert F. Kennedy Jr. “reportedly asked a government vaccines advisory group to scrutinize dozens of aluminum-containing vaccines that have been in use for nearly 100 years.” Aluminum-based adjuvants “are often used in inactivated vaccines, including childhood vaccines against diphtheria, tetanus, and pertussis (Tdap), Haemophilus influenzae type b (Hib), pneumococcal conjugate vaccine (PCV), and hepatitis A and B to boost immune responses, the study authors noted.”

Researchers looked at registry data on childhood vaccinations and “aluminum content, outcomes, and potential confounding factors in the first 2 years of life among more than 1.2 million children born in Denmark from 1997 to 2018.” Only 1.2% of the children received no aluminum-adjuvanted vaccines before age 2. The team looked for “vaccine-related events involving 50 chronic conditions” during follow-up.

The researchers found “no association between cumulative aluminum exposure in vaccines in the first 2 years of life and increased risk of any of the 50 chronic conditions.”